Reuters reports that the US Department of Health and Human Services (HHS) said on Saturday it shall allow state health departments to distribute Gilead Sciences Inc’s remdesivir drug to fight COVID-19.
Key notes
United States would receive about 40% of the drug maker’s global donation.
Gilead has committed to supply approximately 607,000 vials of remdesivir over the next six weeks in the United States, and the U.S. state health department will distribute the doses to appropriate hospitals in their states, HHS said.
Gilead’s drug has shown promise in helping patients infected with COVID-19, the illness caused by the novel coronavirus, and is being closely watched on how the limited supply is distributed.
Gilead Chief Executive Dan O’Day said in late April that Gilead would donate 1.5 million doses and work with the US government on distribution.
On Saturday, HHS said the 1.5 million doses were a global figure and that 607,000 would be distributed through the agency.
The allocation by Gilead Sciences to the United States was finalized on May 3, HHS said.
The U.S. is sending the drug remdesivir to local agencies in Illinois, Iowa, Connecticut, Maryland, Michigan and New Jersey.
Market implications
This is more positive news which could help to buoy markets along with the news of various nations and some states in the US are easing their lockdown measures. USD/JPY has started out on the front foot in the open for the week:
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD holds above 1.0650 after US data
EUR/USD retreats from session highs but manages to hold above 1.0650 in the early American session. Upbeat macroeconomic data releases from the US helps the US Dollar find a foothold and limits the pair's upside.
GBP/USD retreats toward 1.2450 on modest USD rebound
GBP/USD edges lower in the second half of the day and trades at around 1.2450. Better-than-expected Jobless Claims and Philadelphia Fed Manufacturing Index data from the US provides a support to the USD and forces the pair to stay on the back foot.
Gold is closely monitoring geopolitics
Gold trades in positive territory above $2,380 on Thursday. Although the benchmark 10-year US Treasury bond yield holds steady following upbeat US data, XAU/USD continues to stretch higher on growing fears over a deepening conflict in the Middle East.
Ripple faces significant correction as former SEC litigator says lawsuit could make it to Supreme Court
Ripple (XRP) price hovers below the key $0.50 level on Thursday after failing at another attempt to break and close above the resistance for the fourth day in a row.
Have we seen the extent of the Fed rate repricing?
Markets have been mostly consolidating recent moves into Thursday. We’ve seen some profit taking on Dollar longs and renewed demand for US equities into the dip. Whether or not this holds up is a completely different story.